Expanding role of bortezomib in multiple myeloma: Nursing implications

Cancer Nursing

Volumn 31, Issue 3, 2008, Pages 239-249

  Colson, Kathleen ^a   Doss, Deborah S ^a   Swift, Regina ^b   Tariman, Joseph ^c,d  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b James R Berenson MD Inc   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Bortezomib; Management; Multiple myeloma; Nursing; Relapsed; Side effects

Indexed keywords

ACICLOVIR; ALPHA TOCOPHEROL; AMIODARONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ANTIEMETIC AGENT; APPETITE STIMULANT; BARBITURIC ACID DERIVATIVE; BORTEZOMIB; CARBAMAZEPINE; CIMETIDINE; CORTICOSTEROID DERIVATIVE; CORTISONE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DIPHENHYDRAMINE; DOXORUBICIN; ERYTHROMYCIN; FOLIC ACID; GABAPENTIN; HYDROCORTISONE; LOPERAMIDE; MELPHALAN; PARACETAMOL; PREDNISONE; PREGABALIN; PYRROLE DERIVATIVE; RIBOFLAVIN; THALIDOMIDE; THIAMINE;

ABDOMINAL PAIN; ANEMIA; ANOREXIA; ASTHENIA; BONE MARROW SUPPRESSION; BONE PAIN; CANCER CHEMOTHERAPY; CANCER FATIGUE; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; COUGHING; DIARRHEA; DIET THERAPY; DRUG ANTAGONISM; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INHIBITION; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; ELECTROLYTE DISTURBANCE; FATIGUE; FEVER; FOOD DRUG INTERACTION; GASTROINTESTINAL SYMPTOM; GRAPEFRUIT JUICE; HEADACHE; HEALTH CARE PERSONNEL; HEPATITIS; HERPES ZOSTER; HUMAN; HYPOTENSION; INSOMNIA; KIDNEY DYSFUNCTION; KIDNEY FAILURE; LIMB PAIN; LOW DRUG DOSE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NAUSEA; NAUSEA AND VOMITING; NEUROPATHIC PAIN; NEUROPATHY; NEUTROPENIA; ORTHOSTATIC HYPOTENSION; OUTCOME ASSESSMENT; PARESTHESIA; PATIENT EDUCATION; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROPHYLAXIS; QUALITY OF LIFE; RASH; RECOMMENDED DRUG DOSE; RENAL REPLACEMENT THERAPY; REVIEW; RISK FACTOR; THROMBOCYTOPENIA; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; URTICARIA; VITAMIN SUPPLEMENTATION; VOMITING;

ANTINEOPLASTIC AGENTS; BORONIC ACIDS; DEXAMETHASONE; FEMALE; HUMANS; MALE; MULTIPLE MYELOMA; NEOPLASM RECURRENCE, LOCAL; PYRAZINES; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 43249111220     PISSN: 0162220X     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.NCC.0000305733.80592.8e     Document Type: Review

References (50)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics. CA Cancer J Clin. 2007;57(1):43-66.
2. Ries LAG, Eisner MP, Kosary CL, et al. SEER Cancer Statistics Review, 1975-2002. Bethesda, MD: National Cancer Institute; 2005. http://seer.cancer. gov/csr/1975_2002/. Accessed on June 15, 2006.
3. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med. 2004;351(18):1860-1873.
4. Melton LJ III, Kyle RA, Achenbach SJ, Oberg AL, Rajkumar SV. Fracture risk with multiple myeloma: a population-based study. J Bone Miner Res. 2005;20(3):487-493.
5. Knudsen LM, Hippe E, Hjorth M, Holmberg E, Westin J. Renal function in newly diagnosed multiple myeloma - a demographic study of 1353 patients. The Nordic Myeloma Study Group. Eur J Haematol. 1994;53(4):207-212.
6. Adams J, Kauffman M. Development of the proteasome inhibitor Velcade (Bortezomib). Cancer Invest. 2004;22(2):304-311.
7. Colson K, Doss DS, Swift R, Tariman J, Thomas TE. Bortezomib, a newly approved proteasome inhibitor for the treatment of multiple myeloma: nursing implications. Clin J Oncol Nurs. 2004;8(5):473-480.
8. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005;352(24):2487-2498.
9. Richardson P, Sonneveld P, Schuster M, et al. Bortezomib continues to demonstrate superior efficacy compared with high-dose dexamethasone in relapsed multiple myeloma: updated results of the APEX trial. Blood. 2005;106(11):715a.
10. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003;348(26):2609-2617.
11. Richardson PG, Barlogie B, Berenson J. Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma: final time-to-event results from the SUMMIT trial. Cancer. 2006;106(6):1316-1319.
12. Jagannath S, Barlogie B, Berenson J, et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol. 2004;127(2):165-172.
13. Wu KL, van Wieringen W, Vellenga E, Zweegman S, Lokhorst HM, Sonneveld P. Analysis of the efficacy and toxicity of bortezomib for treatment of relapsed or refractory multiple myeloma in community practice. Haematologica. 2005;90(7):996-997.
14. Kropff MH, Bisping G, Wenning D, et al. Bortezomib in combination with dexamethasone for relapsed multiple myeloma. Leuk Res. 2005;29(5):587-590.
15. Spicka I, Hajek R, Vytrasova M, et al. Bortezomib (Velcade) in relapsed/refractory multiple myeloma - the first experience in the Czech Republic. Cas Lek Cesk. 2005;144(9):636, 638-640.
16. Musto P, Falcone A, Sanpaolo G, et al. Bortezomib (Velcade) for progressive myeloma after autologous stem cell transplantation and thalidomide. Leuk Res. 2006;30(3):283-285.
17. Jagannath S, Richardson PG, Barlogie B, et al. Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone. Haematologica. 2006;91(7):929-934.
18. Richardson PG, Mitsiades C, Ghobrial I, Anderson K. Beyond single-agent bortezomib: combination regimens in relapsed multiple myeloma. Curr Opin Oncol. 2006;18(6):598-608.
19. Sood R, Carloss H, Kerr R, et al. Retreatment with bortezomib alone or in combination for patients with multiple myeloma (MM) following an initial response to bortezomib: a phase IV, open-label trial. Ann Oncol. 2006;17(9):ix205-ix206.
20. Millennium Pharmaceuticals Inc. VELCADE® (bortezomib) for Injection. Prescribing information. Cambridge, MA; 2006. Issued December 2006.
21. Berenson JR, Jagannath S, Barlogie B, et al. Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma. Cancer. 2005;104(10):2141-2148.
22. Richardson PG, Briemberg H, Jagannath S, et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol. 2006;24(19):3113-3120.
23. Wisløff F, Hjorth M. Health-related quality of life assessed before and during chemotherapy predicts for survival in multiple myeloma. Nordic Myeloma Study Group. Br J Haematol. 1997;97(1):29-37.
24. Lee SJ, Richardson PG, Sonneveld P, et al. Health-related quality of life (HRQL) associated with bortezomib compared with high-dose dexamethasone in relapsed multiple myeloma (MM): results from APEX study. J Clin Oncol. 2005;23(16S):568s.
25. Lee S, Richardson PG, Barlogie B, et al. Quality-of-life (QOL) and clinical benefit assessment in patients with relapsed and refractory multiple myeloma (MM) treated with bortezomib. Proc Am Soc Clin Oncol. 2003;22:582.
26. Zangari M, Esseltine D, Lee CK, et al. Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma. Br J Haematol. 2005;131(1):71-73.
27. Heider U, Kaiser M, Muller C, et al. Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment. Eur J Haematol. 2006;77(3):233-238.
28. Peles S, Gao F, Tomasson MH, DiPersio JF, Vij R. A prospective study of the effects of once weekly bortezomib on markers of bone metabolism in patients with multiple myeloma. J Clin Oncol. 2006;24(16S):433s.
29. Terpos E, Heath DJ, Rahemtulla A, et al. Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma. Br J Haematol. 2006;135(5):688-692.
30. Bang SM, Lee JH, Yoon SS, et al. A multicenter retrospective analysis of adverse events in Korean patients using bortezomib for multiple myeloma. Int J Hematol. 2006;83(4):309-313.
31. San Miguel J, Blade J, Boccadoro M, et al. A practical update on the use of bortezomib in the management of multiple myeloma. Oncologist. 2006;11(1):51-61.
32. Anderson K, Richardson P, Chanan-Khan A, et al. Single-agent bortezomib in previously untreated multiple myeloma: results of a phase II multicenter study. J Clin Oncol. 2006;24(18S):423s.
33. San Miguel JF, Richardson P, Sonneveld P, et al. Frequency, characteristics, and reversibility of peripheral neuropathy (PN) in the APEX trial. Blood. 2005;106(11):111a.
34. Lonial S, Richardson P, Sonneveld P, et al. Hematologic profiles in the phase 3 APEX trial. Blood. 2005;106(11):970a.
35. Lonial S, Waller EK, Richardson PG, et al. Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood. 2005;106(12):3777-3784.
36. Gerecitano J, Goy A, Wright J, et al. Drug-induced cutaneous vasculitis in patients with non-Hodgkin lymphoma treated with the novel proteasome inhibitor bortezomib: a possible surrogate marker of response? Br J Haematol. 2006;134(4):391-398.
37. Chanan-Khan AA, Sonneveld P, Schuster MW, et al. Analysis of varicella zoster virus reactivation among bortezomib-treated patients in the APEX study. Blood. 2006;108(11):1009a.
38. Tariman JD, Lemoine C. Bortezomib. Clin J Oncol Nurs. 2003;7(6):687-689.
39. Rosinol L, Montoto S, Cibeira MT, Blade J. Bortezomib-induced severe hepatitis in multiple myeloma: a case report. Arch Intern Med. 2005;165(4):464-465.
40. Schwartz R, Davidson T. Pharmacology, pharmacokinetics, and practical applications of bortezomib. Oncology (Huntingt). 2004;18(14 suppl 11):14-21.
41. Bladé J, Fernandez-Llama P, Bosch F, et al. Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern Med. 1998;158(17):1889-1893.
42. Knudsen LM, Hjorth M, Hippe E. Renal failure in multiple myeloma: reversibility and impact on the prognosis. Nordic Myeloma Study Group. Eur J Haematol. 2000;65(3):175-181.
43. Carlson K, Hjorth M, Knudsen LM. Toxicity in standard melphalan-prednisone therapy among myeloma patients with renal failure - a retrospective analysis and recommendations for dose adjustment. Br J Haematol. 2005;128(5):631-635.
44. Jagannath S, Barlogie B, Berenson JR, et al. Bortezomib in recurrent and/or refractory multiple myeloma: initial clinical experience in patients with impaired renal function. Cancer. 2005;103(6):1195-1200.
45. Mulkerin D, Remick S, Ramanathan R, et al. A dose-escalating and pharmacologic study of bortezomib in adult cancer patients with impaired renal function. J Clin Oncol. 2006;24(18S):87s.
46. Chanan-Khan AA, Kaufman JL, Mehta J, et al. Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study. Blood. 2007;109(6):2604-2606.
47. Richardson PG, Sonneveld P, Schuster MW, et al. Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma. Br J Haematol. 2007;137(5):429-435.
48. Richardson PG, Barlogie B, Berenson J, et al. Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma. Blood. 2005;106(9):2977-2981.
49. Jagannath S, Richardson PG, Sonneveld P, et al. Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leukemia. 2007;21(1):151-157.
50. Laura R, Cibeira MT, Uriburu C, et al. Bortezomib: an effective agent in extramedullary disease in multiple myeloma. Eur J Haematol. 2006;76(5):405-408.